AstraZeneca says it plans to participate in the next round of Medicare negotiations under the Inflation Reduction Act. But ...

On the J&J's fourth-quarter earnings call, executives stood by Intra-Cellular’s projection that Caplyta could eclipse $5 ...

The FDA dodged claims from Vanda Pharmaceuticals that it allegedly violated the US Constitution by recommending the same drug ...

A little-known Chinese biotech startup has zipped ahead of US companies in one of the gene editing field’s most competitive ...

Samsung Biologics closed 2024 on several high notes, reaching its highest annual revenue to date — and just a week ago, ...

Quantum Health laid off 4% of workforce shortly after naming Dayne Williams as CEO. The company serves 3M+ members for ...

HHS Secretary nominee Robert F. Kennedy Jr. will divest his interests in several biopharma companies, including CRISPR ...

Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake ...

Xilio's vilastobart plus Roche's Tecentriq shows partial responses in colorectal cancer trial, but company faces cash ...

One of Inhibrx Biosciences’ antibody candidates has shown encouraging early efficacy in colorectal cancer. But its safety is ...

A biotech developing what it says is an “opioid-like” pain reliever released Phase 3 data Wednesday morning claiming the drug ...

J&J's depression drug Spravato hits $1B in 2024 sales, up 56% from 2023, with expanded label approval and 140,000+ patients ...